Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Over 18 years old~2. Has a diagnosis of rheumatoid arthritis~3. Stable DMARDs for at least 1 month (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine)~4. Disease activity score DAS28/ESR \> 3.2 or all must be met: TJC (tender joint count)\>=4, SJC (swollen joint count)\>=4~5. Must be able to understand information in the Informed Consent and comply with study requirements~6. Total ultrasound synovitis (inflammation of joint-lining membrane) power Doppler score \>=1 for at least 2 joints and total synovitis score \>=1 for at least 1 joint~Exclusion Criteria:~1. Current or prior use of biologic drugs (TNF inhibitors, IL-6 inhibitors, CD20 inhibitors, IL-1 inhibitors, etc.)~2. Pregnancy or breast feeding~3. Daily prednisone \> 10mg (stable dose for at least 1 month)~4. Intra-articular steroid injection of the wrist or joints within last 2 months~5. History of a concomitant autoimmune disease such as lupus, psoriatic arthritis~6. History of cancer~7. Previous exposure to abatacept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous Abatacept (Type: EXPERIMENTAL): All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).